SAN FRANCISCO, CA, Feb 04 (MARKET WIRE) --
Linkage Biosciences Inc., a developer of molecular diagnostic products
designed to streamline complex genetic testing, has completed a Series A
financing led by Greenhouse Capital Partners and James R. Fisher,
managing member of Fisher Capital Corp. II LLC, a firm that works
exclusively with private equity firm Kohlberg Kravis Roberts & Co.
The $2 million Series A funding round will be used to continue the
development and marketing of Linkage Biosciences' line of diagnostic
products. The company's proprietary molecular diagnostics technologies and
innovations will address human leukocyte antigen (HLA) typing for organ
transplantation, while further development is underway on a portfolio of
products in other areas of transplantation and various complex genetic
disorders.
"Our unique advantages are speed and simplicity while achieving superior
accuracy," said Zachary Antovich, president and CEO of Linkage
Biosciences. "Our tests generate results much faster, with far less
effort, than anything else available in the marketplace. We are pleased
to have the support and experience of Greenhouse Capital and Jim Fisher
as we begin to commercialize our products and expand our presence in the
marketplace."
"Linkage Biosciences' initial testing has yielded exceptional results in
tissue typing applications, and we now see the company moving to a second
level of growth and development, proving that it can create an entire
portfolio of molecular diagnostic products to bring to market," said Peter
Henig, managing partner of Greenhouse Capital. "We are thrilled to be an
investment partner in the company's growth and execution at this time. We
believe this is an ideal time for Linkage Bioscience to initiate its
market rollout strategy as the technology has surpassed significant
milestones."
The company also announced that Rebecca Bishop and Pascal Villiger have
joined the Board of Directors. Ms. Bishop is currently a manager with
Affymetrix, Inc. and Mr. Villiger is an investment professional within the
private equity division of CalSTRS.
In addition to its Board of Directors, Linkage Biosciences has a highly
regarded Scientific Advisory Board of industry experts, including:
-- F. Carl Grumet, M.D., Emeritus Professor of Pathology and Emeritus
Director, Stanford Histocompatibility Laboratory, Stanford University
-- Clifford Lowell, M.D., Ph.D., Professor and Chair of the Department of
Laboratory Medicine, University of California, San Francisco
-- Rade Drmanac, Ph.D., Chief Science Officer, Complete Genomics
-- David Ginzinger, Ph.D., Principal, DGG Consulting
About Greenhouse Capital Partners
Greenhouse Capital Partners, a seed-stage venture capital firm dedicated
to fostering innovation in cleantech and select other emerging
technologies, provides strategic guidance as well as seed and Series A
financing to companies at their earliest stages of creation. Founded in
2006, Greenhouse Capital is located in Sausalito, California. For more
information, please visit www.greenhousecapital.net.
About Fisher Capital Corp.
Fisher Capital Corp. II LLC, is a private equity firm managed by James R.
Fisher that works exclusively with private equity firm Kohlberg Kravis
Roberts & Co.. Mr. Fisher serves on the Board of Directors of First Data
Corp. and Coverzones Inc. and is a Trustee of Lafayette College, The
American Foundation for the Blind and The National World War II Museum.
About Linkage Biosciences
Linkage Biosciences Inc. is a pioneer in the development of molecular
diagnostic products designed to streamline complex genetic testing. For
more information, please visit www.linkagebio.com.
Media Contact:
Allison Busch
The Blueshirt Group
(415) 489-2192
Email Contact
Copyright 2009, Market Wire, All rights reserved.
-0-
